Compare PBH & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | INSP |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.2B |
| IPO Year | 2005 | 2018 |
| Metric | PBH | INSP |
|---|---|---|
| Price | $66.28 | $65.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 16 |
| Target Price | $85.40 | ★ $127.40 |
| AVG Volume (30 Days) | 399.7K | ★ 1.3M |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.77 |
| EPS | ★ 3.79 | 1.48 |
| Revenue | ★ $1,103,606,000.00 | $882,622,000.00 |
| Revenue This Year | N/A | $15.30 |
| Revenue Next Year | $2.24 | $10.84 |
| P/E Ratio | ★ $17.29 | $44.44 |
| Revenue Growth | N/A | ★ 16.81 |
| 52 Week Low | $57.25 | $65.45 |
| 52 Week High | $90.04 | $203.12 |
| Indicator | PBH | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 26.44 |
| Support Level | $63.69 | $65.45 |
| Resistance Level | $68.62 | $84.24 |
| Average True Range (ATR) | 2.10 | 4.76 |
| MACD | -0.09 | -1.37 |
| Stochastic Oscillator | 39.98 | 4.80 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.